India: The Conundrum Of Compulsory Licensing

Last Updated: 23 March 2016
Article by Akriti Kapoor

The compulsory licensing provision has been in force ever since the inception of Patent Laws in our country. Prior to the implementation of TRIPS provisions in the Indian Patent Law, the Controllers were comparatively liberal in granting compulsory licenses (hereinafter, CL) and India witnessed a fair number of CL's being granted for public greater good if the applicant could satisfactorily prove the need for a CL. Although, the Controllers favour public greater good even today, their decisions are influenced by additional restrictive factors as compared to the times when we were not TRIPS compliant. The case of Bayer v. Natco[1] is a live example, where India faced a lot of criticism from the western world to grant its first CL to an Indian generic. Consequently, the United States Trade Representative Offices 2014 Special Report released on April 30, 2014 placed India on the priority watch list highlighting continuing concerns over India's inadequate protection of foreign Intellectual Property Rights. So it becomes obvious that in the advent of globalization, there are economic, trade and commercial aspects involved as much as the concern for public good when it comes to such laws which affect global interests.

Since, the onus of satisfying the grounds for making an application for a CL lies with the applicant, the question before us is what an applicant needs to do to make a successful case for grant of a CL, as in the recent cases of BDR Pharmaceuticals v. Bristol Myers Squibb[2] (hereinafter, BDR case) and Lee Pharma v. Astrazeneca AB[3] (hereinafter, Lee Pharma case), even a prima facie case could not be made out by the applicants.

Firstly, the applicant can apply for a CL only after three years of the grant of the patent. Secondly, while making such an application, the applicant needs to establish that he is a person interested; has ability to work the invention to the public advantage and has capacity to undertake the risk in providing capital and working the invention if the application was granted. In the BDR case, the applicant proved that he was a person interested as he was into the field of pharmaceutical and had has his own manufacturing and marketing infrastructure. Therefore, he had the capacity to undertake risk in providing capital to manufacture and make Dasatinib (BMS's patented drug) accessible in India. In the Lee pharma case, the applicant stated that he was involved for more than 17 years into the pharmaceutical industry and has a production capability of 10,00,000 tablets of Saxagliptin (Astrazeneca's patented drug) and saxagliptin+metformin XR per day. Therefore, in both the cases, the Controller was satisfied that the applicants were person interested and had capacity to work the invention if the application was granted.

The next critical requirement is that an applicant must have made unqualified efforts to procure a voluntary license (hereinafter VL) from the patentee on reasonable terms and conditions, over a reasonable period of time. In the BDR case, the applicant did not respond to the queries raised by the patentee after making a request for a VL and straight away filed an application for a CL after an year of receipt of Patentee's reply. His application was rejected for lack of efforts in obtaining a VL as an absolute duty is vested upon the applicant to pursue persistent efforts in order to procure a VL for at least six month (the reasonable period stipulated by the act). But in the BDR case, the applicants refrained from any further dialogue on the assumption that it was the patentee's strategy to keep the request for a VL in abeyance by raising multiple queries and seeking information. Had the applicant responded to the patented communication and tried to convince him to agree to mutually agreeable terms, his efforts would have qualified to be reasonable to make the application for a CL. The controller did not further examine the case on merits for failure of the applicant to make efforts to procure a VL. On the contrary, in the Lee Pharma case, the applicant could establish that they made reasonable efforts to obtain a VL in light of their replies to the queries raised by the patentee and a continuous follow up process. Therefore, this case was further examined on merits.

Next, an application for CL is tested for conditions under Section 84(1) of the Patents Act i.e. (a) whether the reasonable requirements of the public have been met; (b) the availability of the patent at an affordable price; and (c) whether the patent has been worked in India or not.

The Lee Pharma case did not meet the requirements of Section 84(1), for the following reasons:

a) The applicant could not demonstrate whether the reasonable requirements of the public were met or not as they could not statistically ascertain the requirements of Saxagliptin in India. Mere assumption of tentative requirement of the drug was considered insufficient and an applicant ought to statistically define the amount of the medication actually prescribed by doctors, the demand of the medicine in the country vis-à-vis the supply etc.

b) The applicant failed to establish that the patented drug was available at an unaffordable price as other substitute drugs were available/being purchased in the same price range in India. Further, even though the applicants submitted revised reasonable selling prices, they failed to provide data w.r.t how many poor patients in India could not access the drug because of the cost issue. Therefore, it is important for the applicant to provide concrete data on the price of drug, price of the available substitute drugs, and probably compare the two vis-à-vis his quoted price to conclude whether the price of the patentee is affordable or not.

c) Since, the applicants failed to show the exact quantitative requirement of saxagliptin in India, it could not be concluded whether manufacturing of the drug in India was necessary or not. It is apparent after the decision of Bayer v. Natco that manufacturing outside India wasn't critical to working of the invention unless the patentee had an unused manufacturing plant in the country itself. Therefore, the applicant ought to demonstrate working of the patent vis-à-vis its demand or supply shortage instead of making a ruckus of the manufacturing or import practices of the patentee.

In light of the above, as the onus to make a case for grant of a CL lied with the applicant, he must ensure that he meets the requirements under the law with strong and relevant evidences and not base his arguments on mere surmises as such application are scrutinized with a broader perspective of their effects on international trade and commerce in addition to public good.

[1] Order 45 of 2013, IPAB

[2] C.L.A No, 1of 2013, Patent Office decision dated October 29, 2013.

[3] C.L.A No, 1of 2015 Patent Office decision dated January 19, 2016.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Nishith Desai Associates
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Nishith Desai Associates
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions